Event-free survival (EFS)
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Hartmut Döhner, Daniela Späth, Maral Saadati, Walter Fiedler, Katharina Götze, Elisabeth Koller, Jörg Westermann, Wichard Vogel, Michael Heuser, Michael Lübbert, Hans-Joachim Tischler, Ulrich Germing, Lino L Teichmann, Lars Fransecky, Albert Wölfler, David Nachbaur, Bernd Hertenstein, Roland Schroers, Uwe Martens, Stephanie von Harsdorf, Markus Radsak, Gregor Aschauer, Stefanie Weißhaar, Andrea Corbacioglu, Anika Schrade, Verena I Gaidzik, Felicitas Thol, Peter Paschka, Lars Bullinger, Axel Benner, Konstanze Döhner, Arnold Ganser
Blood 147(15) 1735-1748
Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT. We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multikinase inhibitor dasatinib in adult patients with CBF-AML. Patients received "3+7" induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg daily on days 8 to 21 in induction, and on days 6 to 28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg daily. Primary end point was event-free survival (EFS). Secondary end points included overall survival, relapse-free survival, and cumulative incidence of relapse. A total of 202 patients were randomly assigned to the standard arm (n = 102) and to the dasatinib arm (n = 100). Median age was 49 years (range, 18-77); 94 patients had t(8;21), 108 had inv(16)/t(16;16); and 58 (28.7%) patients had a KIT comutation. There was no statistically significant difference in EFS (hazard ratio, 0.92; 95% confidence interval, 0.63-1.33; P = .66) or secondary end points between treatment arms. There was also no significant difference in EFS in subgroup analyses according to age, CBF-AML type, and KIT mutation status. The incidence of serious adverse events was higher in the investigational arm (64%) than in the standard arm (36%). In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve survival outcomes. The addition of dasatinib was associated with an increase in toxicity. This trial was registered at www.ClinicalTrials.gov as NCT02013648.
2 个 Figure · 11 个 KM 面板
Figure 2. Primary and secondary end points. (A) EFS in the ITT population. In this EFS analysis, molecular persistence or molecular relapse are considered as treatment failure. There was no statistically significant difference in EFS between treatment arms (HR, 0.92; 95% CI, 0.63-1.33; stratified log-rank test, P = .66). (B) OS. There was no statistically significant difference in OS between treatment arms (HR, 0.93; 95% CI, 0.53-1.63; stratified log-rank test, P = .79). (C) RFS. There was no statistically significant difference in RFS between treatment arms (HR, 0.82; 95% CI, 0.55-1.21; stratified log-rank test, P = .31).
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3. Prespecified subgroup analyses for the primary end point EFS by treatment arm and according to patient subgroups. (A) According to KIT mutation status, mutated vs wt. (B) According to type of CBF-AML, inv(16) vs t(8;21). (C) According to age group, 18 to 60 years vs >60 years. (D) According to sex, male vs female.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel A_2
Panel A_2 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B_4
Panel B_4 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C_6
Panel C_6 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D_8
Panel D_8 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。